{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:48:47Z","timestamp":1785728927961,"version":"3.56.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Chleck Foundation"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002541"],"award-info":[{"award-number":["UL1TR002541"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunocompromised patients remain at risk for protracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections with persistent viral shedding that could pose a wider public health risk. The optimal therapeutic strategy remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We describe a sequential case series of immunocompromised adults with protracted SARS-CoV-2 infection who received dual\/extended antiviral therapy (median 23d nirmatrelvir\/r; 8d remdesivir). Protracted infection was defined as persistent viral shedding and prolonged symptoms unresponsive to antiviral monotherapy in B-cell-depleted patients. Plasma anti-spike immunoglobulin G (IgG) and spike antigen were analyzed using the single molecule array assay (Simoa), viral RNA levels defined by cycle thresholds (Ct) from clinical assays and quantitative RNA polymerase chain reaction (PCR) testing, and whole virus and targeted nsp5\/nsp12 sequencing were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen patients with protracted SARS-CoV-2 infection were treated with dual\/extended antivirals. Viral sequencing supported the presence of protracted infections in all tested, but only 1 participant demonstrated mutations conferring antiviral resistance. Humoral immune responses were blunted both at initiation and completion of therapy. All participants responded to dual\/extended antiviral therapy with negative PCR at a median of 13 days post-treatment, no evidence of virologic recurrence, and no clinical relapse at 1 year. One patient with recurrent positive SARS-CoV-2 testing was demonstrated to have a new infection by sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dual\/extended antiviral therapy with nirmatrelvir\/r and remdesivir can be effective for protracted SARS-CoV-2 infection in B-cell-depleted patients who fail antiviral monotherapy, despite persistently blunted humoral immune responses. Additionally, immunocompromised hosts are at risk of both protracted infection and early re-infection, which can be differentiated by viral sequencing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf383","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T17:23:33Z","timestamp":1752686613000},"page":"1050-1061","source":"Crossref","is-referenced-by-count":5,"title":["Protracted SARS-CoV-2 Infection in B-cell Depleted Patients: Immunologic and Viral Characteristics and Response to Dual and Extended Antiviral Therapy"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-5647","authenticated-orcid":false,"given":"Jessica S","family":"Little","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3415-3167","authenticated-orcid":false,"given":"Gregory E","family":"Edelstein","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Swank","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish C","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-6225","authenticated-orcid":false,"given":"Ella","family":"Borberg","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron T","family":"Nutt","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3777-9744","authenticated-orcid":false,"given":"Hayden S","family":"Andrews","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneerah","family":"Aleissa","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University , Riyadh ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urwah","family":"Kanwal","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine D","family":"Friedman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Piermattei","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Levine","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinki","family":"Deo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7019-343X","authenticated-orcid":false,"given":"Aidan","family":"Eustace","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8487-9731","authenticated-orcid":false,"given":"Scott","family":"Dryden-Peterson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Cosimi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritha","family":"Sen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan A","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E","family":"Woolley","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9914-9662","authenticated-orcid":false,"given":"Jonathan Z","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5524-7348","authenticated-orcid":false,"given":"David R","family":"Walt","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]},{"name":"Wyss Institute for Biologically Inspired Engineering , Harvard University, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6596-0518","authenticated-orcid":false,"given":"Nicolas C","family":"Issa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R","family":"Baden","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C","family":"Sherman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2026071700064815100_ciaf383-B1","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"New Engl J Med"},{"key":"2026071700064815100_ciaf383-B2","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/infdis\/jiab622","article-title":"Yearlong COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B-cell depletion","volume":"225","author":"Nussenblatt","year":"2022","journal-title":"J Infect Dis"},{"key":"2026071700064815100_ciaf383-B3","doi-asserted-by":"crossref","first-page":"ofad278","DOI":"10.1093\/ofid\/ofad278","article-title":"Rapid emergence of potentially transmissible severe acute respiratory syndrome coronavirus 2 with resistance to combination monoclonal antibody therapy","volume":"10","author":"Jacobs","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026071700064815100_ciaf383-B4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New Engl J Med"},{"key":"2026071700064815100_ciaf383-B5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/cid\/ciab380","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequence characteristics of coronavirus disease 2019 (COVID-19) persistence and reinfection","volume":"74","author":"Choudhary","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026071700064815100_ciaf383-B6","doi-asserted-by":"crossref","first-page":"e13914","DOI":"10.1111\/tid.13914","article-title":"De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients","volume":"24","author":"Simons","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"2026071700064815100_ciaf383-B7","doi-asserted-by":"crossref","first-page":"ofac417","DOI":"10.1093\/ofid\/ofac417","article-title":"Immunogenicity of a three-dose primary series of mRNA COVID-19 vaccines in patients with lymphoid malignancies","volume":"9","author":"Sherman","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026071700064815100_ciaf383-B8","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell\u2013depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"2026071700064815100_ciaf383-B9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40472-022-00385-y","article-title":"Immunocompromised patients with protracted COVID-19: a review of \u201clong persisters.\u201d","volume":"9","author":"Dioverti","year":"2022","journal-title":"Curr Transpl Rep"},{"key":"2026071700064815100_ciaf383-B10","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"2026071700064815100_ciaf383-B11","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/cid\/ciab700","article-title":"Incidence, clinical presentation, relapses and outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients treated with anti-CD20 monoclonal antibodies","volume":"74","author":"Calder\u00f3n-Parra","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026071700064815100_ciaf383-B12","doi-asserted-by":"crossref","first-page":"878","DOI":"10.15585\/mmwr.mm7127a3","article-title":"Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19\u2014COVID-NET, 10 states, March 2020\u2013February 2022","volume":"71","author":"Singson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"S1","key":"2026071700064815100_ciaf383-B13","doi-asserted-by":"crossref","first-page":"e14144","DOI":"10.1111\/tid.14144","article-title":"COVID-19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)-T-cell therapy","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"2026071700064815100_ciaf383-B14","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1093\/cid\/ciac722","article-title":"Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae","volume":"76","author":"Swank","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026071700064815100_ciaf383-B15","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.2023.8823","article-title":"Development of a definition of postacute sequelae of SARS-CoV-2 infection","volume":"329","author":"Thaweethai","year":"2023","journal-title":"JAMA"},{"key":"2026071700064815100_ciaf383-B16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/cid\/ciab647","article-title":"Effects of treatment of coronavirus disease 2019 with convalescent plasma in 25 B-cell\u2013depleted patients","volume":"74","author":"Gharbharan","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026071700064815100_ciaf383-B17","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/jac\/dkad144","article-title":"High-titer convalescent plasma plus nirmatrelvir\/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients","volume":"78","author":"Huygens","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026071700064815100_ciaf383-B18","doi-asserted-by":"crossref","first-page":"ciad181","DOI":"10.1093\/cid\/ciad181","article-title":"Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients","volume":"77","author":"Mikulska","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026071700064815100_ciaf383-B19","doi-asserted-by":"crossref","first-page":"E4020","DOI":"10.1093\/cid\/ciaa1637","article-title":"Sustained response after remdesivir and convalescent plasma therapy in a B-cell\u2013depleted patient with protracted coronavirus disease 2019 (COVID-19)","volume":"73","author":"Malsy","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026071700064815100_ciaf383-B20","doi-asserted-by":"crossref","first-page":"ofac064","DOI":"10.1093\/ofid\/ofac064","article-title":"Combination therapy with casirivimab\/imdevimab and remdesivir for protracted SARS-CoV-2 infection in B-cell-depleted patients","volume":"9","author":"Dioverti","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026071700064815100_ciaf383-B21","doi-asserted-by":"crossref","first-page":"ofac382","DOI":"10.1093\/ofid\/ofac382","article-title":"Extended remdesivir infusion for persistent coronavirus disease 2019 infection","volume":"9","author":"Martinez","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026071700064815100_ciaf383-B22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/cid\/ciac847","article-title":"Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised host","volume":"76","author":"Trottier","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026071700064815100_ciaf383-B23","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/cid\/ciae026","article-title":"Clinical and virological outcome of monoclonal antibody therapies across SARS-CoV-2 variants in 245 immunocompromised patients: a multicenter prospective cohort study","volume":"78","author":"Huygens","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026071700064815100_ciaf383-B24","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/s41564-022-01254-1","article-title":"Emergence of SARS-CoV-2 escape mutations during bamlanivimab therapy in a phase II randomized clinical trial","volume":"7","author":"Choudhary","year":"2022","journal-title":"Nat Microbiol"},{"key":"2026071700064815100_ciaf383-B25","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMc2120219","article-title":"Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use","volume":"386","author":"Rockett","year":"2022","journal-title":"New Engl J Med"},{"key":"2026071700064815100_ciaf383-B26","doi-asserted-by":"publisher","author":"Weinstein","year":"2025","DOI":"10.1016\/S1473-3099(25)00221-X"},{"key":"2026071700064815100_ciaf383-B27"},{"key":"2026071700064815100_ciaf383-B28","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1093\/infdis\/jiae174","article-title":"High frequency of prior severe acute respiratory syndrome coronavirus 2 infection by sensitive nucleocapsid assays","volume":"230","author":"Nkolola","year":"2024","journal-title":"J Infect Dis"},{"key":"2026071700064815100_ciaf383-B29","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41551-020-00611-x","article-title":"Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19","volume":"4","author":"Norman","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"2026071700064815100_ciaf383-B30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/cid\/ciab465","article-title":"Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients","volume":"74","author":"Ogata","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026071700064815100_ciaf383-B31","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.7326\/M23-1756","article-title":"SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy\u202f: an observational study","volume":"176","author":"Edelstein","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026071700064815100_ciaf383-B32","doi-asserted-by":"crossref","first-page":"e2435431","DOI":"10.1001\/jamanetworkopen.2024.35431","article-title":"Emerging SARS-CoV-2 resistance after antiviral treatment","volume":"7","author":"Tamura","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026071700064815100_ciaf383-B33","doi-asserted-by":"crossref","first-page":"e0261045","DOI":"10.1371\/journal.pone.0261045","article-title":"Coronavirus resistance database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons","volume":"17","author":"Tzou","year":"2022","journal-title":"PLoS One"},{"key":"2026071700064815100_ciaf383-B34"},{"key":"2026071700064815100_ciaf383-B35"},{"key":"2026071700064815100_ciaf383-B36"},{"key":"2026071700064815100_ciaf383-B37"},{"key":"2026071700064815100_ciaf383-B38","doi-asserted-by":"crossref","first-page":"938","DOI":"10.15585\/mmwr.mm7342a1","article-title":"Genomic surveillance for SARS-CoV-2 variants: circulation of omicron XBB and JN.1 lineages - United States, May 2023\u2013September 2024","volume":"73","author":"Ma","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026071700064815100_ciaf383-B39","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","article-title":"Nextstrain: real-time tracking of pathogen evolution","volume":"34","author":"Hadfield","year":"2018","journal-title":"Bioinformatics"},{"key":"2026071700064815100_ciaf383-B40"},{"key":"2026071700064815100_ciaf383-B41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/2159-8290.CD-21-1033","article-title":"Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov"},{"key":"2026071700064815100_ciaf383-B42","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ajh.26209","article-title":"Prolonged in-hospital stay and higher mortality after COVID-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy","volume":"96","author":"Dul\u00e9ry","year":"2021","journal-title":"Am J Hematol"},{"key":"2026071700064815100_ciaf383-B43","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/hon.3206","article-title":"Dual combined antiviral treatment with remdesivir and nirmatrelvir\/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection","volume":"41","author":"Pasquini","year":"2023","journal-title":"Hematol Oncol"},{"key":"2026071700064815100_ciaf383-B44","doi-asserted-by":"crossref","first-page":"ofad189","DOI":"10.1093\/ofid\/ofad189","article-title":"Successful treatment of prolonged severe acute respiratory syndrome coronavirus 2 infection in patients with immunodeficiency with extended nirmatrelvir\/ritonavir: case series","volume":"10","author":"Breeden","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026071700064815100_ciaf383-B45","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/cid\/ciac868","article-title":"Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a B cell acute lymphoblastic leukemia patient with an extended course of remdesivir and nirmatrelvir\/ritonavir","volume":"76","author":"Ford","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026071700064815100_ciaf383-B46","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/cid\/ciad085","article-title":"Successful combination treatment for persistent severe acute respiratory syndrome coronavirus 2 infection","volume":"76","author":"Blennow","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026071700064815100_ciaf383-B47","first-page":"344267","article-title":"B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience","volume":"11","author":"D\u2019Abramo","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026071700064815100_ciaf383-B48","doi-asserted-by":"crossref","first-page":"eadk1599","DOI":"10.1126\/scitranslmed.adk1599","article-title":"SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency","volume":"16","author":"Li","year":"2024","journal-title":"Sci Transl Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf383\/63778991\/ciaf383.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/6\/1050\/63778991\/ciaf383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/6\/1050\/63778991\/ciaf383.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:07:00Z","timestamp":1784261220000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/6\/1050\/8203483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,7,16]]},"published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf383","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,15]]},"published":{"date-parts":[[2025,7,16]]}}}